KING OF PRUSSIA, Pa.--(BUSINESS WIRE)--Trevena, Inc., the leader in the discovery of G-protein coupled receptor (GPCR) biased ligands, announced that results have been published from a new preclinical pharmacology study of its phase 2 clinical acute heart failure molecule, TRV027. The study was the second to be published as part of a multi-year collaboration between Trevena and Drs. John C. Burnett, Jr, and Guido Boerritger, of the Mayo Clinic.
